Rapalogs and mTOR inhibitors as anti-aging therapeutics

Dudley W Lamming1, Lan Ye, David M Sabatini

  • 1Whitehead Institute for Biomedical Research, Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Insights

Rapamycin shows promise for anti-aging in mammals by extending lifespan. However, its unclear mechanisms and side effects necessitate developing safer mTOR-targeting therapies like rapalogs.

Area of Science:

  • Gerontology and aging research
  • Pharmacology and drug discovery
  • Molecular biology and signaling pathways

Background:

  • Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), is a leading candidate for anti-aging therapies.
  • It has demonstrated lifespan extension in genetically heterogeneous mice, a robust model for aging studies.
  • Despite its efficacy, the precise mechanisms of action and potential side effects in humans remain significant concerns.

Purpose of the Study:

  • To review the current evidence supporting rapamycin as an anti-aging therapeutic.
  • To discuss the limitations and side effects associated with rapamycin treatment.
  • To explore future directions in developing safer mTOR-targeting anti-aging strategies.

Main Methods:

  • Review of existing scientific literature on rapamycin and mTOR signaling.
  • Analysis of experimental data from mammalian aging studies, particularly in mice.
  • Evaluation of potential therapeutic strategies based on rapamycin analogs (rapalogs) and other mTOR pathway modulators.

Main Results:

  • Rapamycin consistently extends mean and maximum lifespan in long-lived, genetically heterogeneous mice.
  • The underlying molecular mechanisms responsible for rapamycin's life-extending effects are not fully elucidated.
  • Rapamycin is associated with a notable list of side effects, questioning its direct applicability in human anti-aging interventions.

Conclusions:

  • While rapamycin offers strong evidence for anti-aging effects in mammals, its clinical use is limited by safety concerns and unclear mechanisms.
  • Future anti-aging therapies should focus on developing rapalogs or alternative mTOR pathway inhibitors with improved safety profiles.
  • Targeting mTOR signaling remains a promising avenue for interventions aimed at promoting longevity and healthspan.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...